Vimseltinib is an investigational new drug that is being evaluated to treat tenosynovial giant cell tumor.[1] It is a macrophage colony-stimulating factor receptor antagonist.[2]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H25N7O2 |
Molar mass | 431.500 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Vimseltinib - Deciphera Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, et al. (October 2022). "Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)". Bioorganic & Medicinal Chemistry Letters. 74: 128928. doi:10.1016/j.bmcl.2022.128928. PMID 35961460.